-
MAPS Submits Revised Marijuana/PTSD Protocol to FDA
-
MAPS Addresses FDA Concerns about Planned Marijuana/PTSD Study
-
NIDA Claims to Have Marijuana Required for Marijuana/PTSD Study
-
Study MJP1 on clinical hold
-
MJP1 clinical hold
-
MJP1 clinical hold
-
Marijuana for PTSD Protocol Submitted to FDA and NIDA
-
Marijuana/PTSD Study Gains Julie Holland, M.D., as Medical Monitor
-
MAPS Receives IND # for Marijuana
-
MAPS New Marijuana/PTSD Study Design Finalized
-
New Marijuana-for-PTSD Protocol Close to Complete